Compliance and Globalism in the age of Brexit and the Trump Administration – Thoughts from Our CEO

Global compliance in life science companies

Recently, our CEO & President, Michaeline Daboul, shared her thoughts on the intersection of ethics, compliance and globalism in the age of Brexit and the Trump administration with the United Kingdom’s Laboratory News.

Life science companies are forging uncharted territory with the murky state of global compliance laws after Brexit and speculation of deregulation under the Trump administration.

While Brexit leaves the U.K. able to avoid compliance with the E.U.’s General Data Protection Regulation (GDPR), Trump’s unfavorable comments on the Foreign Corrupt Practices Act (FCPA) leave some wondering if there will be an end to strict enforcement of U.S. regulation laws. 

However, Daboul argues that compliance is simply the right thing to do – regardless of whether politics demand it. Life science companies are in the business of helping patients receive the best care possible, and with this commitment comes a commitment to ethics.

“Life science companies that want to succeed regardless of the political situation should practice trickle-down ethics. Support of compliance – being honest and having scruples – should come from the top of the organization and make its way down to middle management and beyond.”

To read more of Daboul’s feature on life science companies, compliance and why “Good Guys Finish First,” visit page 36 of the latest edition of Laboratory News.

Michaeline Daboul

CEO, Co-founder of MMIS, Inc.

Posted on Jun 13, 2017 3:06:00 PM

Share This Story, Choose Your Platform!

Click Here
MediSpend Blog



Want to learn more about how our solutions can help your company?